Background: Amyotrophic Lateral Sclerosis (ALS) is a fatal neurodegenerative disease of the motor neuron for which no clinically validated biomarkers have been identified. Methods: We have quantified by ELISA the biomarker phosphoneurofilament heavy chain (pNFH) in the cerebrospinal fluid (CSF) of ALS patients (n. =. 29) and age-matched control patients with other diseases (n. =. 19) by ELISA. Furthermore, we compared protein N-glycosylation of the CSF in ALS patients and controls, by applying a glycomics approach based on liquid chromatography and mass spectrometry. Results: pNFH levels were significantly higher in ALS patients in comparison with controls (P.
|Number of pages||8|
|Journal||Clinica chimica acta; international journal of clinical chemistry|
|Publication status||Published - 1 Jan 2015|
- Amyotrophic lateral sclerosis
- Cerebrospinal fluid
- Phosphoneurofilament heavy chain